QZQingjing Zeng

Qingjing Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qingjing Zeng has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Jia Liu

    Department of Ultrasound Guangdong Key Laboratory of Liver Disease Research Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou China

    1 shared publication
  • Kai Li

    Department of Ultrasound, Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    1 shared publication
  • Lu Li

    Department of Ultrasound, The Second Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, People’s Republic of China

    1 shared publication
  • Rongqin Zheng

    The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    1 shared publication

Latest Publications

  • Prevention of major biliary complications by fusion imaging for thermal ablation of malignant liver tumors adjacent to the bile ducts: a preliminary comparative study

    by Jia Liu, Lu Li, Qingjing Zeng, Rongqin Zheng, Kai Li

    Purpose Ultrasound (US)-guided thermal ablation (TA) may cause major biliary complications, particularly in patients with malignant liver tumors (MLTs) adjacent to the bile ducts. Fusion imaging (FI), is postulated to reduce complication rate; however, there is a lack of clinical data to support this theory. Thus, the aim of our study was to evaluate the safety and efficacy of FI for TA of MLTs proximal to the bile ducts. Methods A retrospective single-center review was conducted on a total of 289 patients with 316 MLTs adjacent to the bile ducts. The patients were divided into two groups based on whether FI was used in the ablation procedures. The choice of the FI-assisted procedure always depends on different operation periods and whether registrations will succeed. The baseline demographics and outcomes of these patients were compared. The efficacy was determined at the 1-month follow-up using contrast-enhanced computed tomography/magnetic resonance. Biliary complications and local tumor progression were subsequently followed-up every 3–6 months. The last follow-up visit was before August 30, 2019. Results Among the included tumors, the incidence rate of major biliary complications after ablation in the FI group was 1.6%, which was significantly lower than that in the non-FI group (7.9%, p = 0.005). There was no significant difference in the efficacy rates of the techniques [99.5% (185/186) versus 98.4% (123/125), p = 0.56] or local progression rates [3.8% (7/185) versus 5.7% (7/123), p = 0.61] between the FI and non-FI groups. Conclusion FI for US-guided TA could be a noninvasive means to decrease major biliary complications. Trial registration number and date of registration: retrospectively registered. Graphical abstract